EXEL Exelixis, Inc. Stock Quote

EXEL [NASD]

Index	-	P/E	68.02	EPS (ttm)	0.35	Insider Own	1.30%	Shs Outstand	310.77M	Perf Week	3.08%
Market Cap	7.52B	Forward P/E	22.57	EPS next Y	1.05	Insider Trans	-17.59%	Shs Float	306.21M	Perf Month	3.85%
Income	111.80M	PEG	-	EPS next Q	0.03	Inst Own	85.40%	Short Float	4.25%	Perf Quarter	0.06%
Sales	987.50M	P/S	7.61	EPS this Y	-65.50%	Inst Trans	1.29%	Short Ratio	6.54	Perf Half Y	1.37%
Book/sh	6.05	P/B	3.92	EPS next Y	163.66%	ROA	5.40%	Target Price	31.36	Perf Year	22.12%
Cash/sh	3.81	P/C	6.23	EPS next 5Y	-	ROE	6.10%	52W Range	18.18 - 27.80	Perf YTD	18.29%
Dividend	-	P/FCF	42.08	EPS past 5Y	19.70%	ROI	4.80%	52W High	-12.07%	Beta	1.05
Dividend %	-	Quick Ratio	7.00	Sales past 5Y	92.70%	Gross Margin	96.30%	52W Low	34.46%	ATR	0.80
Employees	773	Current Ratio	7.10	Sales Q/Q	12.40%	Oper. Margin	11.20%	RSI (14)	62.78	Volatility	3.21% 3.49%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-59.30%	Profit Margin	11.30%	Rel Volume	0.65	Prev Close	23.74
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 10 AMC	Payout	0.00%	Avg Volume	1.99M	Price	24.44
Recom	1.90	SMA20	6.01%	SMA50	7.50%	SMA200	9.39%	Volume	1,142,519	Change	2.97%

Mar-31-21

Initiated

Credit Suisse

Outperform

$30

Mar-12-21

Initiated

Wolfe Research

Outperform

$35

Mar-04-20

Initiated

Barclays

Overweight

$26

Jan-13-20

Initiated

SunTrust

Buy

$31

Nov-13-19

Initiated

BofA/Merrill

Buy

$22

Mar-18-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Sep-17-18

Initiated

Goldman

Neutral

$22

Sep-10-18

Initiated

Morgan Stanley

Underweight

$19

May-11-18

Reiterated

Needham

Buy

$33 → $30

Oct-17-17

Reiterated

RBC Capital Mkts

Outperform

$33 → $39

Oct-17-17

Reiterated

Needham

Buy

$30 → $33

Oct-16-17

Reiterated

SunTrust

Buy

$32 → $35

Sep-22-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$32

Sep-12-17

Reiterated

Needham

Buy

$28 → $30

Jul-14-17

Initiated

SunTrust

Buy

$33

Mar-31-17

Initiated

Needham

Buy

$28

Mar-16-17

Initiated

Oppenheimer

Perform

Feb-28-17

Downgrade

Stifel

Buy → Hold

$21 → $22

Nov-03-16

Initiated

Deutsche Bank

Buy

$17

Apr-08-21 05:51AM	3 Growth Stocks That'll Make You Richer in Q2 (and Beyond) Motley Fool
Apr-06-21 12:33PM	Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA Zacks
Apr-05-21 08:00AM	Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors Business Wire
Apr-01-21 12:21PM	Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo Zacks
12:04PM	Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK Benzinga
Mar-31-21 01:01AM	Exelixis Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire
Mar-30-21 08:00AM	Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma Business Wire
Mar-27-21 06:45AM	3 Exciting Biotech Stocks to Buy Right Now Motley Fool
Mar-19-21 09:17AM	Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC Zacks
08:41AM	Exelixis Partners With Merck KGaA And Pfizer For STELLAR-001 Clinical Trial SmarterAnalyst
Mar-18-21 09:10AM	Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma Benzinga
08:00AM	Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma Business Wire
Mar-12-21 11:30AM	Why Is Exelixis (EXEL) Up 3.4% Since Last Earnings Report? Zacks
Mar-10-21 03:08AM	Introducing Exelixis (NASDAQ:EXEL), The Stock That Soared 487% In The Last Five Years Simply Wall St.
Mar-08-21 08:00AM	Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Business Wire
Feb-26-21 06:30AM	Exelixis Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire
Feb-25-21 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March Business Wire
08:00AM	Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Business Wire
Feb-19-21 04:07PM	Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021 Business Wire
Feb-17-21 06:06AM	Got $500? 3 Smart Stocks You Can Buy Right Now Motley Fool
Feb-16-21 09:01AM	Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer Benzinga
Feb-13-21 01:00PM	Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU Business Wire
Feb-12-21 05:15PM	Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors Business Wire
Feb-11-21 03:00PM	Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss Zacks
07:00AM	Exelixis Inc (EXEL) Q4 2020 Earnings Call Transcript Motley Fool
Feb-10-21 05:55PM	Exelixis (EXEL) Q4 Earnings Surpass Estimates Zacks
04:40PM	Recap: Exelixis Q4 Earnings Benzinga
04:05PM	Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Business Wire
02:45PM	Exelixis, Inc. to Host Earnings Call ACCESSWIRE
Feb-09-21 04:08PM	Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium Business Wire
10:16AM	Earnings Outlook For Exelixis Benzinga
07:13AM	Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study Benzinga
Feb-08-21 05:00PM	OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial Business Wire
05:00PM	Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma Business Wire
10:01AM	Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-04-21 04:05PM	Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 11, 2021 Business Wire
Feb-03-21 12:31PM	Earnings Preview: Exelixis (EXEL) Q4 Earnings Expected to Decline Zacks
Feb-01-21 08:00AM	Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles Business Wire
Jan-29-21 05:51AM	Got $4,000? 4 Growth Stocks Begging to Be Bought Motley Fool
Jan-27-21 04:05PM	Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021 Business Wire
11:05AM	Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates Zacks
Jan-25-21 09:24AM	Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC Zacks
08:00AM	Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors Business Wire
Jan-22-21 07:44PM	Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC Motley Fool
01:10PM	Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire
Jan-11-21 09:48AM	Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates Zacks +5.83%
Jan-10-21 04:00PM	Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021 Business Wire
06:06AM	3 Top Biotech Picks for 2021 Motley Fool
Jan-09-21 05:51AM	5 Value Stocks That Will Make You Richer in 2021 Motley Fool
Jan-04-21 04:05PM	Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 Business Wire
Dec-31-20 06:05AM	3 Healthcare Stocks That Are Screaming Buys in 2021 Motley Fool
Dec-28-20 01:51AM	What Kind Of Investors Own Most Of Exelixis, Inc. (NASDAQ:EXEL)? Simply Wall St.
Dec-23-20 06:06AM	3 Beaten-Down Growth Stocks That Can Soar in 2021 Motley Fool
Dec-22-20 04:37PM	Is EXEL A Good Stock To Buy According To Hedge Funds? Insider Monkey
10:39AM	Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study Zacks
Dec-21-20 11:55AM	Should Investors Consider This Biotech Takeover Target? Motley Fool
07:30AM	Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer Business Wire
Dec-19-20 06:09AM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Dec-16-20 08:00AM	XWPharma Names Michael M. Morrissey, PhD to Board of Directors GlobeNewswire
Dec-08-20 01:32PM	Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND Zacks
Dec-07-20 08:00AM	Exelixis In-Licenses Aurigenes Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors Business Wire
Dec-05-20 11:32AM	Why Is Exelixis (EXEL) Down 14.4% Since Last Earnings Report? Zacks
Dec-02-20 08:00AM	Exelixis In-Licenses Iconic Therapeutics Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application Business Wire
Nov-27-20 08:00AM	Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy Business Wire
05:51AM	Got $50? 4 Smart Stocks to Buy Into Right Now Motley Fool
Nov-23-20 05:30PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December Business Wire
Nov-11-20 08:24AM	New Strong Sell Stocks for November 11th Zacks
Nov-06-20 03:01PM	Exelixis Inc (EXEL) Q3 2020 Earnings Call Transcript Motley Fool -6.54%
10:33AM	Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat Zacks
07:50AM	Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? Simply Wall St.
Nov-05-20 08:30PM	Exelixis (EXEL) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire
03:45PM	Exelixis, Inc. to Host Earnings Call ACCESSWIRE
Nov-03-20 12:46PM	Were These Hedge Funds Wrong About Exelixis, Inc. (EXEL)? Insider Monkey
06:32AM	Is Exelixis Stock a Buy? Motley Fool
05:51AM	4 Safe Stocks to Buy and Hold for the Next 4 Years Motley Fool
Nov-02-20 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November Business Wire
Oct-29-20 12:34PM	Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-20 06:57AM	Better Buy: Illumina vs. Exelixis Motley Fool
04:38AM	Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised) Zacks
Oct-27-20 08:24AM	The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga
01:02AM	Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan Business Wire
Oct-26-20 08:00AM	Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors Business Wire
Oct-22-20 04:05PM	Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020 Business Wire
Oct-20-20 10:57AM	Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC Zacks
Oct-19-20 04:27PM	Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment Investor's Business Daily
06:59AM	U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma Business Wire
Oct-17-20 06:06AM	4 Stocks Robinhood Investors Should Buy and Hold for 5 Years Motley Fool
Oct-13-20 09:12AM	2 Great Stocks to Buy With Just $100 Motley Fool
07:49AM	3 Safe Stocks for a Coming Market Crash Motley Fool
Oct-09-20 03:02AM	Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor Business Wire
03:01AM	Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor Business Wire
Oct-07-20 07:21AM	These Are the 3 Biggest Bargains in Biotech Motley Fool
Oct-06-20 02:23PM	Why Exelixis Jumped 10% in September Motley Fool
Oct-03-20 06:55AM	Next Coronavirus Market Crash: Where to Invest $10,000 Motley Fool
Oct-02-20 05:51AM	The 3 Best Stocks to Invest $100 in Right Now Motley Fool
Sep-21-20 10:20AM	Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab Business Wire
05:51AM	The Best Stocks to Invest $1,000 In When the Market Is Falling Motley Fool
Sep-19-20 12:30PM	Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial Business Wire
Sep-18-20 06:05PM	Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study Reuters

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 01	Option Exercise	1.70	50,000	85,000	663,482	Apr 02 07:41 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Apr 01	Option Exercise	1.70	60,000	102,000	449,467	Apr 02 07:51 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 01	Sale	23.00	50,000	1,150,000	613,482	Apr 02 07:41 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Apr 01	Sale	22.96	60,000	1,377,600	389,467	Apr 02 07:51 PM
WYSZOMIERSKI JACK L	Director	Mar 29	Option Exercise	3.38	40,000	135,200	237,809	Mar 31 09:02 PM
WYSZOMIERSKI JACK L	Director	Mar 29	Sale	22.64	6,220	140,821	231,589	Mar 31 09:02 PM
Garber Alan M	Director	Mar 15	Option Exercise	3.38	40,000	135,200	52,718	Mar 17 08:11 PM
Garber Alan M	Director	Mar 15	Sale	23.60	40,000	944,000	12,718	Mar 17 08:11 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Mar 01	Option Exercise	1.70	65,000	110,500	405,072	Mar 03 07:49 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Mar 01	Sale	22.11	65,000	1,437,150	340,072	Mar 03 07:49 PM
COHEN CHARLES	Director	Feb 24	Option Exercise	3.38	40,000	135,200	221,375	Feb 26 08:10 PM
COHEN CHARLES	Director	Feb 24	Sale	22.69	40,000	907,600	181,375	Feb 26 08:10 PM
WILLSEY LANCE	Director	Feb 23	Option Exercise	3.38	40,000	135,200	464,415	Feb 24 08:11 PM
WILLSEY LANCE	Director	Feb 23	Sale	21.93	40,000	877,136	424,415	Feb 24 08:11 PM
POSTE GEORGE	Director	Feb 22	Option Exercise	3.38	40,000	135,200	197,992	Feb 24 08:18 PM
MARCHESI VINCENT T	Director	Feb 22	Sale	22.29	24,097	537,122	66,115	Feb 24 08:15 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 18	Option Exercise	1.70	50,000	85,000	590,597	Feb 19 07:57 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 18	Sale	22.35	50,000	1,117,500	540,597	Feb 19 07:57 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 17	Option Exercise	1.70	50,000	85,000	590,597	Feb 19 07:57 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 17	Sale	22.50	50,000	1,125,000	540,597	Feb 19 07:57 PM
FELDBAUM CARL B	Director	Feb 16	Option Exercise	3.38	20,000	67,600	28,521	Feb 17 08:03 PM
FELDBAUM CARL B	Director	Feb 16	Sale	21.96	20,000	439,200	8,521	Feb 17 08:03 PM
WILLSEY LANCE	Director	Feb 16	Sale	21.90	50,000	1,095,000	424,415	Feb 24 08:11 PM
Haley Patrick J.	EVP, Commercial	Feb 12	Sale	21.57	45,000	970,650	246,887	Feb 17 08:15 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Feb 01	Option Exercise	1.70	65,000	110,500	348,124	Feb 03 07:57 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Feb 01	Sale	22.08	65,000	1,435,200	283,124	Feb 03 07:57 PM
Senner Christopher J.	EVP and CFO	Jan 12	Option Exercise	3.66	30,000	109,800	275,596	Jan 14 08:22 PM
Senner Christopher J.	EVP and CFO	Jan 12	Sale	25.00	30,000	750,000	245,596	Jan 14 08:22 PM
Hessekiel Jeffrey	EVP and General Counsel	Jan 04	Option Exercise	5.12	50,000	256,100	541,754	Jan 06 08:22 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jan 04	Option Exercise	1.70	65,000	110,500	348,124	Jan 06 08:40 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jan 04	Sale	20.32	65,000	1,320,800	283,124	Jan 06 08:40 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Dec 18	Option Exercise	1.70	65,000	110,500	348,124	Dec 22 07:58 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Dec 18	Sale	20.01	65,000	1,300,650	283,124	Dec 22 07:58 PM
WILLSEY LANCE	Director	Dec 04	Option Exercise	5.82	106,142	617,746	474,415	Dec 04 07:56 PM
MARCHESI VINCENT T	Director	Nov 24	Option Exercise	5.82	40,004	232,823	130,216	Nov 25 07:46 PM
MARCHESI VINCENT T	Director	Nov 24	Sale	18.50	40,004	740,074	90,212	Nov 25 07:46 PM
Hessekiel Jeffrey	EVP and General Counsel	Nov 15	Option Exercise	7.27	30,000	218,100	494,254	Nov 17 08:00 PM
WYSZOMIERSKI JACK L	Director	Nov 10	Option Exercise	5.82	62,403	363,185	231,809	Nov 13 08:18 PM
WYSZOMIERSKI JACK L	Director	Nov 10	Sale	20.61	34,000	700,740	197,809	Nov 13 08:18 PM
Hessekiel Jeffrey	EVP and General Counsel	Oct 21	Option Exercise	7.27	39,742	288,924	382,768	Oct 23 08:08 PM
Hessekiel Jeffrey	EVP and General Counsel	Oct 21	Sale	21.95	39,742	872,337	343,026	Oct 23 08:08 PM
Senner Christopher J.	EVP and CFO	Oct 08	Option Exercise	3.66	10,000	36,600	137,882	Oct 09 08:04 PM
Senner Christopher J.	EVP and CFO	Oct 08	Sale	25.00	10,000	250,000	127,882	Oct 09 08:04 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 22	Option Exercise	7.27	10,258	74,576	353,284	Sep 24 08:03 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 22	Sale	26.14	10,258	268,144	343,026	Sep 24 08:03 PM
Haley Patrick J.	EVP, Commercial	Sep 21	Option Exercise	5.82	4,680	27,238	120,251	Sep 23 08:12 PM
Haley Patrick J.	EVP, Commercial	Sep 21	Sale	26.09	4,680	122,101	115,571	Sep 23 08:12 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 16	Option Exercise	7.27	20,000	145,400	363,026	Sep 16 08:24 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 16	Sale	26.11	20,000	522,200	343,026	Sep 16 08:24 PM
Senner Christopher J.	EVP and CFO	Sep 15	Option Exercise	3.66	20,000	73,200	147,882	Sep 15 08:03 PM
Senner Christopher J.	EVP and CFO	Sep 15	Sale	25.00	20,000	500,000	127,882	Sep 15 08:03 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 08	Option Exercise	5.18	249,692	1,293,315	503,692	Sep 10 08:39 PM
COHEN CHARLES	Director	Sep 01	Option Exercise	5.82	115,396	671,605	181,375	Sep 03 08:05 PM
POSTE GEORGE	Director	Aug 14	Option Exercise	5.82	29,662	172,633	157,992	Aug 14 07:50 PM
MORRISSEY MICHAEL	President and CEO	Jul 20	Option Exercise	6.21	100,000	621,000	185,985	Jul 22 07:06 PM
Haley Patrick J.	EVP, Commercial	Jul 20	Sale	25.36	3,151	79,909	112,189	Jul 22 07:01 PM
MORRISSEY MICHAEL	President and CEO	Jul 10	Option Exercise	6.21	100,000	621,000	185,985	Jul 10 08:48 PM
MORRISSEY MICHAEL	President and CEO	Jun 19	Option Exercise	6.21	100,000	621,000	185,985	Jun 19 09:20 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jun 08	Option Exercise	5.51	26,000	143,260	152,531	Jun 10 08:19 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jun 08	Sale	22.56	26,000	586,560	126,531	Jun 10 08:19 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Jun 04	Option Exercise	1.70	100,000	170,000	425,963	Jun 05 08:00 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Jun 04	Sale	22.96	100,000	2,296,000	325,963	Jun 05 08:00 PM
MORRISSEY MICHAEL	President and CEO	May 29	Option Exercise	6.21	100,000	621,000	185,985	May 29 09:36 PM
Garber Alan M	Director	May 22	Sale	24.42	36,111	881,831	12,718	May 22 08:53 PM
MARCHESI VINCENT T	Director	May 21	Option Exercise	5.82	40,000	232,800	130,212	May 22 09:11 PM
MARCHESI VINCENT T	Director	May 21	Sale	24.64	40,000	985,600	90,212	May 22 09:11 PM
Haley Patrick J.	EVP, Commercial	May 20	Sale	24.99	3,151	78,743	115,340	May 22 08:17 PM
WILLSEY LANCE	Director	May 18	Option Exercise	4.58	30,000	137,400	398,273	May 20 08:36 PM
WILLSEY LANCE	Director	May 18	Sale	26.26	30,000	787,800	368,273	May 20 08:36 PM
SCANGOS GEORGE A	Director	May 18	Sale	25.96	75,000	1,947,000	714,717	May 20 08:35 PM
MORRISSEY MICHAEL	President and CEO	May 15	Option Exercise	6.21	100,000	621,000	185,985	May 15 09:29 PM
SCANGOS GEORGE A	Director	May 15	Option Exercise	5.10	51,686	263,613	789,717	May 15 08:31 PM
WILLSEY LANCE	Director	May 14	Option Exercise	5.92	15,000	88,800	383,273	May 15 08:19 PM
WILLSEY LANCE	Director	May 14	Sale	25.26	15,000	378,900	368,273	May 15 08:19 PM
Hessekiel Jeffrey	EVP and General Counsel	May 13	Option Exercise	1.70	25,000	42,500	264,188	May 15 08:20 PM
PAPADOPOULOS STELIOS	Director	May 13	Option Exercise	5.82	120,791	703,004	1,173,359	May 15 08:18 PM
Hessekiel Jeffrey	EVP and General Counsel	May 11	Option Exercise	1.90	38,006	72,211	277,194	May 11 08:36 PM
MARCHESI VINCENT T	Director	May 11	Option Exercise	4.58	30,000	137,400	112,484	May 13 09:16 PM
MARCHESI VINCENT T	Director	May 11	Sale	26.30	30,000	789,000	82,484	May 13 09:16 PM
Hessekiel Jeffrey	EVP and General Counsel	May 11	Sale	27.09	38,006	1,029,583	239,188	May 11 08:36 PM
Senner Christopher J.	EVP and CFO	May 08	Option Exercise	3.66	78,583	287,614	199,286	May 08 09:22 PM
Haley Patrick J.	EVP, Commercial	May 08	Option Exercise	1.76	21,375	37,620	139,866	May 08 09:16 PM
PAPADOPOULOS STELIOS	Director	May 08	Option Exercise	5.03	45,000	226,200	1,097,568	May 08 09:18 PM
Hessekiel Jeffrey	EVP and General Counsel	May 08	Option Exercise	1.90	25,000	47,500	264,188	May 11 08:36 PM
Hessekiel Jeffrey	EVP and General Counsel	May 08	Sale	26.04	25,000	651,000	239,188	May 11 08:36 PM
Senner Christopher J.	EVP and CFO	May 08	Sale	25.81	78,583	2,028,227	120,703	May 08 09:22 PM
Haley Patrick J.	EVP, Commercial	May 08	Sale	25.87	21,375	552,971	118,491	May 08 09:16 PM
PAPADOPOULOS STELIOS	Director	May 08	Sale	25.84	45,000	1,162,800	1,052,568	May 08 09:18 PM
Lamb Peter	EVP, Scientific Strategy & CSO	May 07	Option Exercise	5.51	50,000	275,500	176,531	May 08 09:11 PM
POSTE GEORGE	Director	May 07	Option Exercise	5.82	30,000	174,600	142,792	May 08 09:13 PM
FELDBAUM CARL B	Director	May 07	Option Exercise	4.27	31,546	134,798	40,067	May 08 09:14 PM
Senner Christopher J.	EVP and CFO	May 07	Option Exercise	3.66	21,417	78,386	142,120	May 08 09:22 PM
Hessekiel Jeffrey	EVP and General Counsel	May 07	Option Exercise	1.90	30,000	57,000	269,188	May 11 08:36 PM
Hessekiel Jeffrey	EVP and General Counsel	May 07	Sale	25.61	30,000	768,300	239,188	May 11 08:36 PM
Senner Christopher J.	EVP and CFO	May 07	Sale	25.80	21,417	552,559	120,703	May 08 09:22 PM
FELDBAUM CARL B	Director	May 07	Sale	25.02	31,546	789,281	8,521	May 08 09:14 PM
POSTE GEORGE	Director	May 07	Sale	25.61	30,000	768,300	112,792	May 08 09:13 PM
Lamb Peter	EVP, Scientific Strategy & CSO	May 07	Sale	25.54	50,000	1,277,000	126,531	May 08 09:11 PM
MORRISSEY MICHAEL	President and CEO	May 06	Option Exercise	1.70	285,284	484,983	371,269	May 08 09:10 PM
MORRISSEY MICHAEL	President and CEO	Apr 27	Option Exercise	1.70	285,000	484,500	370,985	Apr 29 08:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience